|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1990-6-20
|
|
pubmed:abstractText |
The forty participants in a double blind controlled trial of parenteral methotrexate or gold for RA were followed up two years later. Fifty percent had remained on the original medication, 13/20 on MTX and 7/20 on gold. Only 5 and 3 of them respectively had no active joint swelling. No major differences between the two groups were seen.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0392-856X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
163-6
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:2110877-Arthritis, Rheumatoid,
pubmed-meshheading:2110877-Drug Administration Schedule,
pubmed-meshheading:2110877-Follow-Up Studies,
pubmed-meshheading:2110877-Gold Sodium Thiomalate,
pubmed-meshheading:2110877-Humans,
pubmed-meshheading:2110877-Infusions, Parenteral,
pubmed-meshheading:2110877-Methotrexate,
pubmed-meshheading:2110877-Patient Dropouts,
pubmed-meshheading:2110877-Time Factors
|
|
pubmed:articleTitle |
Parenteral methotrexate or gold for rheumatoid arthritis: a follow up.
|
|
pubmed:affiliation |
Department of Medicine, University of Alberta, Canada.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
